Y-mAbs Therapeutics
YMAB
YMAB was delisted on the 15th of September, 2025.
91 hedge funds and large institutions have $375M invested in Y-mAbs Therapeutics in 2022 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 34 increasing their positions, 26 reducing their positions, and 8 closing their positions.
43,000% more call options, than puts
Call options by funds: $2.59M | Put options by funds: $6K
63% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 8
31% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 26
25% more capital invested
Capital invested by funds: $301M → $375M (+$74.1M)
3% more funds holding
Funds holding: 88 → 91 (+3)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
1.25% less ownership
Funds ownership: 57.89% → 56.64% (-1.2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Walleye Capital
New York
|
+$4.86M |
| 2 |
PA
Perceptive Advisors
New York
|
+$2.47M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.58M |
| 4 |
Invesco
Atlanta,
Georgia
|
+$1.17M |
| 5 |
Millennium Management
New York
|
+$954K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$6.6M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$3.85M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$2.74M |
| 4 |
Morgan Stanley
New York
|
-$1.95M |
| 5 |
AllianceBernstein
Nashville,
Tennessee
|
-$1.79M |
YMAB Hedge Fund Activity: Q2 2022 in Review
91 of the 5,960 institutional investors tracked by Wall St. Rank reported a position in Y-mAbs Therapeutics (YMAB) for Q2 2022, worth a combined $375M — up 25% from $301M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new YMAB positions and 8 closed out — a net gain of 5 holders — while 34 added to existing stakes and 26 trimmed.
The largest buyer was Walleye Capital, opening a new position worth an estimated $4.86M. The largest seller was State Street, cutting an estimated $6.6M.
- 91 institutional investors held Y-mAbs Therapeutics (YMAB) as of Q2 2022, up from 88 in Q1 2022.
- Funds reported $375M of Y-mAbs Therapeutics stock for Q2 2022, up 25% quarter-over-quarter.
- 13 funds opened new Y-mAbs Therapeutics positions in Q2 2022 and 8 closed out, a net change of +5 holders.
- The largest Y-mAbs Therapeutics buyer in Q2 2022 was Walleye Capital, an estimated $4.86M added.
- The largest Y-mAbs Therapeutics seller in Q2 2022 was State Street, an estimated $6.6M sold.
Based on aggregated 13F filings for Q2 2022.